LVW Advisors LLC Has $587,000 Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

LVW Advisors LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.9% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,320 shares of the medical equipment provider’s stock after purchasing an additional 119 shares during the quarter. LVW Advisors LLC’s holdings in Intuitive Surgical were worth $587,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after buying an additional 493,126 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Intuitive Surgical by 1.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after buying an additional 272,741 shares in the last quarter. Capital World Investors increased its stake in Intuitive Surgical by 1.0% during the 1st quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after acquiring an additional 73,634 shares during the period. Edgewood Management LLC boosted its holdings in shares of Intuitive Surgical by 7.9% in the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after purchasing an additional 374,667 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in Intuitive Surgical by 2.0% in the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock valued at $1,516,222,000 after buying an additional 88,977 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ISRG has been the topic of several research analyst reports. The Goldman Sachs Group began coverage on Intuitive Surgical in a research report on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Citigroup boosted their target price on Intuitive Surgical from $462.00 to $512.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. Stifel Nicolaus lifted their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research report on Friday, July 19th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Finally, Truist Financial boosted their price target on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $442.30.

Intuitive Surgical Stock Down 0.2 %

Shares of Intuitive Surgical stock traded down $1.10 during trading on Tuesday, hitting $464.43. The stock had a trading volume of 134,987 shares, compared to its average volume of 1,556,126. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $470.49. The company has a market capitalization of $164.73 billion, a PE ratio of 84.43, a P/E/G ratio of 4.97 and a beta of 1.39. The stock has a 50 day simple moving average of $438.40 and a 200 day simple moving average of $405.13.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.18 EPS. As a group, equities analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $387.22, for a total value of $67,763.50. Following the sale, the senior vice president now directly owns 533 shares in the company, valued at $206,388.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 584 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $404.41, for a total transaction of $236,175.44. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,226,681.46. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Mark Brosius sold 175 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $387.22, for a total value of $67,763.50. Following the transaction, the senior vice president now owns 533 shares in the company, valued at approximately $206,388.26. The disclosure for this sale can be found here. In the last quarter, insiders have sold 15,307 shares of company stock valued at $6,623,651. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.